Microgyn, Bayer Pharma AG, Germany) was prescribed for 8 days before (semaglutide-free) and during the last week of dosing with semaglutide 1.0 mg (steady-state)
Common side effects observed in Phase 2 trials include nausea, vomiting, diarrhoea, and injection site reactions, particularly during dose escalation
For context on the broader landscape, understanding how mazdutide compares to tirzepatide and how cagrilintide fits in shows just how active the GLP-1 research space has become
Understanding that these side effects are biologically predictable, not random, is the first step toward managing them effectively
Origin of familial malignant melanomas from heritable melanocytic lesions
Tasty & Convenient: Chewable gummy form makes it easy and enjoyable to take daily